Evidence map›Paper›PMID 37978492›Full record

ArticleRespiratory research2023

Baseline characteristics from a 3-year longitudinal study to phenotype subjects with COPD: the FOOTPRINTS study.

James D Crapo, Abhya Gupta, David A Lynch, Alice M Turner, Robert M Mroz, Wim Janssens, Andrea Ludwig-Sengpiel, Harald Koegler, Anastasia Eleftheraki, Frank Risse and 1 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Respiratory research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02719184 (Observational Study in Healthy Subjects and Patients With COPD to Assess the Relationship Between Clinical, Imaging and Biomarker Measurements, and Progression of Emphysema Over Three Years [FOOTPRINTS®].), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02719184 completednot on this map

Observational Study in Healthy Subjects and Patients With COPD to Assess the Relationship Between Clinical, Imaging and Biomarker Measurements, and Progression of Emphysema Over Three Years [FOOTPRINTS®].

TypeobservationalSponsorBoehringer IngelheimRan2016 to 2021Enrolled463ConditionsPulmonary Disease, Chronic Obstructive, Pulmonary Emphysema
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Review
  5. COPD-Lung Cancer Comorbidity: Mechanistic Insights and Precision Oncology Implications.International journal of chronic obstructive pulmonary disease · 2026
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 5 countries.

James D CrapoDepartment of Medicine, National Jewish Health, Denver, CO, USA. crapoj@njhealth.org.
Abhya GuptaTA Inflammation Medicine, Boehringer Ingelheim International GmbH, Biberach an Der Riss, Germany.
David A LynchDepartment of Radiology, National Jewish Health, Denver, CO, USA.
Alice M TurnerInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Robert M Mroz2nd Department of Lung Diseases and Tuberculosis, Bialystok Medical University, Bialystok, Poland.
Wim JanssensDepartment of Chronic Diseases and Metabolism (CHROMETA), Laboratory of Respiratory Diseases and Thoracic Surgery (BREATH), University Hospital Leuven, Louvain, KU, Belgium.
Andrea Ludwig-SengpielKLB Gesundheitsforschung Lübeck GmbH, Lübeck, Germany.
Harald KoeglerTA Inflammation Medicine, Boehringer Ingelheim International GmbH, Ingelheim, Germany.
Anastasia EleftherakiDepartment of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an Der Riss, Germany.
Frank RisseDepartment of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an Der Riss, Germany.
Claudia DiefenbachDepartment of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an Der Riss, Germany.
Boehringer Ingelheim (Germany) · DENational Jewish Health · USKU Leuven · BEMedical University of Białystok · PLUniversity of Birmingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFOOTPRINTS

methodsThe methodology of FOOTPRINTS

resultsIn total, 463 subjects were enrolled. The per-protocol set comprised 456 subjects, mostly male (64.5%). The mean (standard deviation) age was 60.7 (6.9) years. At baseline, increasing pulmonary symptoms, worse lung function, increased residual volume, reduced diffusing capacity of the lung for carbon monoxide (DLco) and greater prevalence of centrilobular emphysema were observed with increasing disease severity amongst GOLD 1-3 subjects. Subjects with A1ATD (n = 19) had similar lung function parameters to GOLD 2-3 subjects, a high residual volume comparable to GOLD 3 subjects, and similar air trapping to GOLD 2 subjects. Compared with EwAL (n = 61), subjects with A1ATD had worse lung function, increased residual volume, reduced DLco, and a greater prevalence of confluent or advanced destructive emphysema. The soluble inflammatory biomarkers white blood cell count, fibrinogen, high-sensitivity C-reactive protein and plasma surfactant protein were higher in GOLD 1-3 groups than in the EwAL group. Interleukin-6 was expressed less often in EwAL subjects compared with subjects in the GOLD and A1ATD groups. Soluble receptor for advanced glycation end product was lowest in GOLD 3 subjects, indicative of more severe emphysema.

conclusionsThese findings provide context for upcoming results from FOOTPRINTS TRIAL REGISTRATION NUMBER: NCT02719184, study start date 13/04/2016.

Indexed as

alpha 1-Antitrypsin DeficiencyPulmonary Disease, Chronic ObstructivePulmonary EmphysemaBiomarkersFemaleForced Expiratory VolumeHumansLongitudinal StudiesLungMaleMiddle AgedPhenotypeProspective StudiesBiomarkersAlpha 1 antitrypsin deficiencyBaseline characteristicsBiomarkersChronic obstructive pulmonary diseaseDisease progressionEmphysemaFOOTPRINTS®

Identifiers

PMID37978492
PMCPMC10656819
OpenAlexW4388762457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.